Recombinant human collagen (Shanxi Jinbo Biomedical)

Given the exponential growth of the recombinant human collagen market, it is paramount to devise a robust and straightforward design strategy aimed at preserving the remarkable biological activity of recombinant human collagen while endowing it with tailored mechanical properties and stable morphologies. This innovative approach stands to broaden its applicability in hard tissue repair endeavors. Our study employed a synergistic approach of alkali hydrolysis and Schiff's base chemistry to graft Type I recombinant human collagen (rhCol-I) onto poly (L-lactic acid) (PLLA) membranes, yielding PLLA-rhCol composites. In vitro evaluations substantiated that this reengineered material not only retained the biological efficacy of rhCol-I but also imparted mechanical robustness and processability ideal for bone implant applications. Notably, it exhibited superior tissue engineering attributes, fostering proliferation, adhesion, osteogenic differentiation, mineralization of bone marrow mesenchymal stem cells (BMSCs), and encouraging vascularization. In a rat model of critical-sized bone defects, PLLA-rhCol exhibited markedly enhanced bone repair efficiency over conventional PLLA bone implants, achieving a bone volume fraction (BV/TV) of up to 32.57 ± 3.77 %, while promoting angiogenesis and effectively mitigating inflammatory cell infiltration. This pioneering method of modifying recombinant human collagen onto the side chains of polymeric macromolecules portends broad applicability in enhancing various biocompatible, yet mechanically robust and processable polymers, thereby expanding the horizons of recombinant human collagen utilization in tissue engineering and catering to the ever-evolving market demands.

According to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth?

Non-interventional study comparing the effectiveness of r-hFSH and recombinant r-hLH (2:1 ratio) versus r-hFSH alone for ovarian stimulation during ART treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register.

Overall clinical pregnancy (29.8%, 95% CI 28.2 to 31.6 versus 27.8%, 95% CI 26.5 to 29.2) and live birth (20.3%, 95% CI 18.7 to 21.8 versus 18.0%, 95% CI 16.6 to 19.4) rates were not significantly different between the combined r-hFSH and r-hLH group and the r-hFSH alone group (P = 0.269 and P = 0.092, respectively). Treatment effect was significantly higher for combined r-hFSH and r-hLH compared with r-hFSH alone for clinical pregnancy (33.1%, 95% CI 31.0 to 35.0 versus 28.5%, 95% CI 26.6 to 30.4; P = 0.001, not adjusted for multiplicity) and live birth (22.5%, 95% CI 20.5 to 24.2 versus 19.4%, 95% CI 17.6 to 20.9; P = 0.014, not adjusted for multiplicity) in a post-hoc analysis of women with five to 14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of combined r-hFSH and r-hLH for ovarian stimulation in women aged 35-40 years with normal ovarian reserve.

Women of AMA with normal ovarian response benefit from treatment with combined r-hFSH and r-hLH in a 2:1 ratio versus r-hFSH alone in terms of live birth rate. The effectiveness of treatments is best assessed by RCTs; however, real-world data are valuable for examining the effectiveness of fertility treatment, especially among patient groups that are not well represented in clinical trials.